Form 8-K - Current report:
SEC Accession No. 0001193125-22-238444
Filing Date
2022-09-06
Accepted
2022-09-06 08:21:02
Documents
14
Period of Report
2022-09-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d350937d8k.htm   iXBRL 8-K 23372
2 EX-99.1 d350937dex991.htm EX-99.1 11916
6 GRAPHIC g350937g45g24.jpg GRAPHIC 3979
  Complete submission text file 0001193125-22-238444.txt   162692

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tcrt-20220906.xsd EX-101.SCH 2844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrt-20220906_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrt-20220906_pre.xml EX-101.PRE 10804
8 EXTRACTED XBRL INSTANCE DOCUMENT d350937d8k_htm.xml XML 3229
Mailing Address 8030 EL RIO STREET HOUSTON TX 77054
Business Address 8030 EL RIO STREET HOUSTON TX 77054 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 221226955
SIC: 2834 Pharmaceutical Preparations